TherapeuticsMD, Inc. — Director's Dealing 2021

May 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-05-10

Reporting Person: Donegan Michael C (CAO and VP Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-10	Common Stock	M	19000	—	Acquired	19000	Direct
2021-05-11	Common Stock	S	4842	$1.04	Disposed	14158	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-10	Restricted Stock Units	$0	M	19000	Disposed		Common Stock (19000)	Direct

Footnotes

F1: On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.

F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.